| Literature DB >> 31013095 |
Xiaqing Zhou1, Tzu-Lan Chang1, Shuang Chen1, Tianchi Liu1, Haoyu Wang1, Jun F Liang1.
Abstract
Orlistat, an FDA-approved antiobesity drug, has recently been shown to have anticancer effects. However, orlistat is extremely hydrophobic with low absorption. Therefore, new approaches are needed to effectively deliver orlistat for cancer therapy. Herein, we developed a fast and simple method to use polydopamine-coated hollow capsule (PHC) as a drug nanocarrier for enhancing the therapeutic effects of orlistat. Orlistat-loaded PHC had an average size of 200 nm, which was characterized by using dynamic light scattering and scanning electron microscope. Furthermore, the polydopamine layer provided an excellent control of orlistat release because it was extremely sensitive to pH values. The cellular uptake and cytotoxicity experiments were performed to show that orlistat packaged in PHC could be endocytosed into cells and then significantly improved the cytotoxic activity against cancer cell lines in a short time compared with free orlistat. Moreover, dynamic study of cell membrane lysis was performed by staining with the LIVE/DEAD kit to demonstrate the cancer-killing mechanism. The size of the cell surface area has also been proven to be a key parameter which affected drug efficacy. Taken all together, these results present that orlistat-loaded PHC is a very promising formula for cancer treatments.Entities:
Keywords: cancer therapy; controlled release; hollow capsule; nanoparticle; orlistat; polydopamine
Mesh:
Substances:
Year: 2019 PMID: 31013095 DOI: 10.1021/acs.molpharmaceut.9b00116
Source DB: PubMed Journal: Mol Pharm ISSN: 1543-8384 Impact factor: 4.939